Citations

Showing 10 of 108104 citations.

Morphometric Study of Pulmonary Arterial Changes in Pulmonary Langerhans Cell Histiocytosis
Bois, Melanie C. , May, Adam M. , Vassallo, Robert , Jenkins, Sarah M. , Yi, Eunhee S. , Roden, Anja C. , Vassallo, Robert , May, Adam M

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 24, 2018 | Volume: 142 | Issue: 8 | Pages: 929-937

10.5858/arpa.2017-0463-oa | PMID 30040456 Get It

Context.— Pulmonary hypertension (PHT) is a complication of pulmonary Langerhans cell histiocytosis (PLCH); however, the pathogenesis remains largely unknown. Few studies have evaluated histopathologic changes in pulmonary arteries (PAs) of patients with PLCH; systematic quantification of arterial remodeling has yet to be undertaken. Objective.— To quantify the extent of arterial remodeling among patients with PLCH through morphometry and to correlate these results with pertinent clinical parameters. Design.— Patients with PLCH were identified from institutional files (1995–2015) along with age-, sex-, and smoking status–matched controls. Morphometric analysis of intimal and medial thickness of small to medium PAs was performed in patients with PLCH (within PLCH lesions [lesional] and away from PLCH lesions [nonlesional]) and controls. Paired measures were compared with Wilcoxon signed rank tests. Results.— Twenty-five patients with PLCH (14 men: median age, 46 years; interquartile range, 37–55 years) and 25 controls were included. The lesional arteries of patients with PLCH demonstrated thicker PA intima and media than controls (P < .001 and P < .001, respectively), as did PLCH nonlesional arteries compared to controls (P < .001 and P < .001, respectively). The PA intima and media were thicker within the PLCH lesions than nonlesional arteries (P = .02 and P = .002, respectively). Patients with PLCH-related PHT had a worse prognosis than those without PHT (P = .04; hazard ratio, 4.5 [1.1, 22.2]). Echocardiography parameters including right atrial size (P = .007), estimated right atrial pressure (P = .01), and right ventricular systolic pressure (P = .01) were inversely associated with survival. Conclusions.— Our findings suggest that factors other than direct vascular obstruction or inflammatory cell infiltration contribute, at least in part, to the vascular remodeling in PLCH.
Development of Vitamin D Toxicity from Overcorrection of Vitamin D Deficiency: A Review of Case Reports
Galior, Kornelia , Grebe, Stefan K., Grebe, Stefan, Singh, Ravinder J.

Mayo Clinic

Nutrients | July 24, 2018 | Volume: 10 | Issue: 8 | Pages: 953

10.3390/nu10080953 | PMID 30042334 Get It

Over the past two decades, vitamin D level measurements have become some of the most frequently ordered tests in the laboratory. This increase is due to a growing awareness of widespread vitamin D deficiency and scientific data suggesting the beneficial effects of vitamin D in various diseases. A literature search was carried out in PubMed for cases reporting vitamin D intoxication and overdose. Thirteen articles were included in this review. Intoxication was severe in the reported cases. Patients presented with serum vitamin D concentrations ranging between 150 and 1220 ng/mL and serum calcium concentrations between 11.1 and 23.1 mg/dL. Most of the reported patients showed symptoms of vitamin D toxicity such as vomiting, dehydration, pain, and loss of appetite. The underlying causes included manufacturing errors, overdosing by patients or prescribers, and combinations of these factors. Our literature search highlights the fact that even though vitamin D intoxication is rare, it does occur and therefore patients and prescribers should be more cognizant of the potential dangers of vitamin D overdose.
Faculty Opinions recommendation of Supraphysiologic administration of GDF11 induces cachexia in part by upregulating GDF15.
LeBrasseur, Nathan K.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732632802.793547987 Get It

Primary myelofibrosis: 2019 update on diagnosis, risk‐stratification and management
Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | July 24, 2018 | Volume: 93 | Issue: 12 | Pages: 1551-1560

10.1002/ajh.25230 | PMID 30039550 Get It

AbstractDisease overviewPrimary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional disease features include bone marrow stromal reaction including reticulin fibrosis, abnormal cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival.DiagnosisDiagnosis of PMF is based on bone marrow morphology. Presence of JAK2, CALR, or MPL mutation, expected in ∼ 90% of the patients, is supportive but not essential for diagnosis. The revised 2016 World Health Organization (WHO) classification system distinguishes “prefibrotic” from “overtly fibrotic” PMF; the former might mimic ET in its presentation and it is prognostically relevant to distinguish the two.Risk stratificationTwo new prognostic systems for PMF have recently been introduced: GIPSS (genetically inspired prognostic scoring system) and MIPSS70+ version 2.0 (mutation‐ and karyotype‐enhanced international prognostic scoring system). GIPSS is based exclusively on mutations and karyotype. MIPSS70+ version 2.0 utilizes both genetic and clinical risk factors. GIPSS features four and MIPSS70+ version 2.0 five risk categories. MIPSS70+ version 2.0 requires an online score calculator (http://www.mipss70score.it) while GIPPS offers a lower complexity prognostic tool.Risk‐adapted therapyObservation alone is advised for MIPSS70+ version 2.0 “low” and “very low” risk disease (estimated 10‐year survival 56%‐92%); allogeneic stem cell transplant is the preferred treatment of choice for “very high” and “high” risk disease (estimated 10‐year survival 0‐13%); treatment‐requiring patients with intermediate‐risk disease (estimated 10‐year survival 30%) are best served by participating in clinical trials. All other treatment approaches, including the use of JAK2 inhibitors, are mostly palliative and should not be used in the absence of clear treatment indications. Conventional treatment for anemia includes androgens, prednisone, thalidomide and danazol, for symptomatic splenomegaly hydroxyurea and ruxolitinib and for constitutional symptoms ruxolitinib. Splenectomy is considered for drug‐refractory splenomegaly and involved field radiotherapy for nonhepatosplenic EMH and extremity bone pain.
Clinical and histopathologic manifestations of solid organ transplantation‐associated graft‐versus‐host disease involving the skin: A single‐center retrospective study
Kim, Grace Y. , Schmelkin, Leah A., Davis, Mark D.P., Wieland, Carilyn N. , Leise, Michael D. , Meves, Alexander , Lehman, Julia S. , Davis, Mark D., El-Azhary, Rokea A, Meves, Alexander , Lehman, Julia S , el‐Azhary, Rokea A.

Mayo Clinic

Journal of Cutaneous Pathology | July 24, 2018 | Volume: 45 | Issue: 11 | Pages: 817-823

10.1111/cup.13326 | PMID 30039546 Get It

BackgroundGraft‐versus‐host disease (GVHD) following solid organ transplantation (SOT) is extremely rare and infrequently described in the dermatologic literature.MethodsWe performed a retrospective clinicopathologic review of our institution's experience with patients diagnosed with SOT‐associated GVHD (SOT GVHD) (May 1, 1996 to September 1, 2017).ResultsOf nine patients with SOT GVHD, seven had undergone liver transplantation, while two had undergone lung transplantation. All presented initially with a skin eruption, which developed an average of 63 days (range: 11‐162 days) post transplant. The average time to diagnosis following the onset of the skin eruption was 12 days (range: 0‐54 days). Diagnosis was often delayed because of a competing diagnosis of drug reaction. Frequent skin findings included pruritic erythematous to violaceous macules and papules with desquamation. Histopathology showed vacuolar interface dermatitis in 12 of 15 cases (80.0%). Of the 11 specimens in which a hair follicle was present for evaluation, vacuolar interface changes around the hair follicle were present in eight (72.7%) cases. Seven patients (77.8%) died from complications during the follow‐up period.ConclusionsSOT GVHD presents initially with skin involvement, is associated with vacuolar interface changes on skin biopsy, and is associated with a high mortality rate. Clinicopathologic correlation is required for accurate diagnosis.
Medicare Beneficiary Out-of-Pocket Costs for Generic Cardiovascular Medications Available Through $4 Generic Drug Discount Programs
Liu, Patrick , Dhruva, Sanket S. , Shah, Nilay D. , Ross, Joseph S. , Ross, Joseph S

Mayo Clinic

Annals of Internal Medicine | July 24, 2018 | Volume: 169 | Issue: 11 | Pages: 817-819

10.7326/m18-0965 | PMID 30039170 Get It

Selecting and Interpreting Alcohol Biomarker Tests: Enough to Drive You to Drink
Jannetto, Paul J.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 6 | Pages: 827-829

10.1373/jalm.2017.025593 | PMID 33636818 Get It

Multicenter Evaluation of Helicobacter pylori IgG Antibody Seroprevalence Among Patients Seeking Clinical Care in the US
Jalaly, Jalal B. , Couturier, Marc Roger , Gronowski, Ann M., Munigala, Satish , Theel, Elitza S. , Burnham, Carey‐Ann D.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 6 | Pages: 904-913

10.1373/jalm.2017.025569 | PMID 33636820 Get It

Abstract Background Current American College of Gastroenterology (ACG) guidelines suggest that Helicobacter pylori serologic testing may be helpful to rule out H. pylori in areas with low disease prevalence. However, even in low prevalence regions, the positive predictive value of a positive serologic result remains low. Additionally, both the ACG and the American Gastroenterological Association recommend that this noninvasive testing be avoided entirely for patients 55 years and older. Methods The objective of this multicenter retrospective study was to assess H. pylori seroprevalence rates among symptomatic patients and serologic test utilization at the local, state, and national level. Submitted specimens were presumed to be collected from patients with upper gastrointestinal symptoms suspicious for an H. pylori etiology. Results for H. pylori IgG serologic tests performed between 2005 and 2014 were collected from 5 medical centers. Data were evaluated in the context of professional practice guidelines, with a focus on patients ages 55 years and older. Results Nationwide seropositivity among symptomatic individuals is approximately 25%, and 4 of 5 centers reported decreasing seropositivity rates over this 10-year period. State-specific seropositivity among symptomatic patients ranged from 12.4% in the state of Washington to 33.9% in Mississippi. Conclusions We demonstrate that for 48 states >25% of all H. pylori serologic testing was performed in individuals ≥55 years. Despite recommendations to avoid serologic evaluation for H. pylori infection, this study indicates that serology continues to be used at high rates across age-groups.